110 related articles for article (PubMed ID: 20108129)
1. Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer.
Forde P; Murphy C; O'Sullivan C; Carney D
Ir J Med Sci; 2011 Mar; 180(1):283-4. PubMed ID: 20108129
[TBL] [Abstract][Full Text] [Related]
2. Trichomegaly secondary to erlotinib.
Desai RU; Rachakonda LP; Saffra NA
Can J Ophthalmol; 2009 Dec; 44(6):e65. PubMed ID: 20052001
[No Abstract] [Full Text] [Related]
3. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva).
Márquez G; Herrera-Acosta E; Vidal I; Galvany L; Iglesias M; Umbert P
Int J Dermatol; 2009 Jan; 48(1):97-8. PubMed ID: 19126063
[No Abstract] [Full Text] [Related]
4. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer.
Carser JE; Summers YJ
J Thorac Oncol; 2006 Nov; 1(9):1040-1. PubMed ID: 17409992
[No Abstract] [Full Text] [Related]
5. Erlotinib-associated trichomegaly.
Lane K; Goldstein SM
Ophthalmic Plast Reconstr Surg; 2007; 23(1):65-6. PubMed ID: 17237698
[TBL] [Abstract][Full Text] [Related]
6. Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
Vergou T; Stratigos AJ; Karapanagiotou EM; Matekovits AE; Dilana KD; Tsimboukis S; Antoniou C; Chasapi V; Syrigos KN
J Am Acad Dermatol; 2010 Aug; 63(2):e56-8. PubMed ID: 20633793
[No Abstract] [Full Text] [Related]
7. Trichomegaly induced by erlotinib.
Papadopoulos R; Chasapi V; Bachariou A
Orbit; 2008; 27(4):329-30. PubMed ID: 18716976
[TBL] [Abstract][Full Text] [Related]
8. Hair growth after gefitinib treatment.
Lee LW; Burt PA
Clin Oncol (R Coll Radiol); 2005 Sep; 17(6):492-3. PubMed ID: 16149296
[No Abstract] [Full Text] [Related]
9. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
Braiteh F; Kurzrock R; Johnson FM
J Clin Oncol; 2008 Jul; 26(20):3460-2. PubMed ID: 18612164
[No Abstract] [Full Text] [Related]
10. Erlotinib-associated alopecia in a lung cancer patient.
Costa DB; Kobayashi S; Schumer ST
J Thorac Oncol; 2007 Dec; 2(12):1136-8. PubMed ID: 18090591
[No Abstract] [Full Text] [Related]
11. Toxicity manifesting as cosmetic hair alterations during erlotinib treatment.
Kudo K; Fujiwara K; Tsushima M; Mizuta M; Matsuo K; Yonei T; Sato T
Acta Oncol; 2011 Jan; 50(1):146-8. PubMed ID: 20843170
[No Abstract] [Full Text] [Related]
12. Ocular side effects and trichomegaly of eyelashes induced by erlotinib: a case report and review of the literature.
Celik T; Kosker M
Cont Lens Anterior Eye; 2015 Feb; 38(1):59-60. PubMed ID: 25249292
[TBL] [Abstract][Full Text] [Related]
13. Persistent hair growth during treatment with the EGFR inhibitor erlotinib.
Alexandrescu DT; Kauffman CL; Dasanu CA
Dermatol Online J; 2009 Mar; 15(3):4. PubMed ID: 19379648
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer.
Belani CP
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S6. PubMed ID: 15638958
[No Abstract] [Full Text] [Related]
15. Acquired trichomegaly: trichomegaly secondary to erlotinib.
Medina Mendez CA; Ma PC; Singh AD
JAMA Ophthalmol; 2014 Sep; 132(9):1051. PubMed ID: 25078467
[No Abstract] [Full Text] [Related]
16. Erlotinib-induced trichomegaly in a male patient with pancreatic cancer.
Saif MW; Gnanaraj J
Cutan Ocul Toxicol; 2010 Mar; 29(1):62-6. PubMed ID: 19954400
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor-induced hirsutism and trichomegaly.
Munoz J; Hanbali AS
Mayo Clin Proc; 2011 Nov; 86(11):e50. PubMed ID: 22033260
[No Abstract] [Full Text] [Related]
18. Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine.
Akiyama N; Karayama M; Iwaizumi M; Kusama Y; Kono M; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Suda T
Intern Med; 2017 Sep; 56(17):2367-2371. PubMed ID: 28794362
[TBL] [Abstract][Full Text] [Related]
19. Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.
Bugés C; Carcereny E; Moran T; Cardona AF; Reguart N; Capdevila L; Cros S; Rosell R
Clin Lung Cancer; 2015 Mar; 16(2):e1-3. PubMed ID: 25550194
[No Abstract] [Full Text] [Related]
20. Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
Byrne BJ; Garst J
Curr Oncol Rep; 2005 Jul; 7(4):241-7. PubMed ID: 15946581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
